Details of the Drug Combination

General Information of Drug Combination (ID: DC5I0RU)

Drug Combination Name
Dihydroergotamine Valproic Acid
Indication
Disease Entry Status REF
Migraine in Children Phase 2 [1]
Component Drugs Dihydroergotamine   DM5IKUF Valproic Acid   DMS49KH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Dihydroergotamine
Disease Entry ICD 11 Status REF
Cluster headache 8A81.0 Approved [2]
Migraine 8A80 Approved [3]
Migraine disorder N.A. Approved [2]
Dihydroergotamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [6]
------------------------------------------------------------------------------------
Dihydroergotamine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Valproic Acid
Disease Entry ICD 11 Status REF
Absence epilepsy N.A. Approved [4]
Epilepsy 8A60-8A68 Approved [4]
Glioblastoma 2A00 Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [5]
Neuroblastoma 2D11.2 Investigative [4]

References

1 ClinicalTrials.gov (NCT03885154) Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine
2 Dihydroergotamine FDA Label
3 Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
4 Valproic Acid FDA Label
5 Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.
6 Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94.
7 CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.